Clinical Trial Detail

NCT ID NCT00892190
Title Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Pittsburgh
Indications

bone marrow cancer

acute myeloid leukemia

Therapies

Dasatinib

Age Groups: adult

No variant requirements are available.